The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

This rising trend mirrors the evolution of the pharmaceutical industry in terms of investment and utilisation of novel ...

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts ...

The Food and Drug Administration has ignited a heated debate with its latest review of menthol cigarettes, revealing ...

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...

Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

(RTTNews) - Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has accepted for review Biologics License Applications ...